Literature DB >> 25821657

Hematopoietic Stem Cell Transplantation for Severe Combined Immunodeficiency.

Justin T Wahlstrom1, Christopher C Dvorak1, Morton J Cowan1.   

Abstract

Hematopoietic stem cell transplantation (HSCT) is an effective approach for the treatment of severe combined immunodeficiency (SCID). However, SCID is not a homogeneous disease, and the treatment required for successful transplantation varies significantly between SCID subtypes and the degree of HLA mismatch between the best available donor and the patient. Recent studies are beginning to more clearly define this heterogeneity and how outcomes may vary. With a more detailed understanding of SCID, new approaches can be developed to maximize immune reconstitution, while minimizing acute and long-term toxicities associated with chemotherapy conditioning.

Entities:  

Year:  2015        PMID: 25821657      PMCID: PMC4371740          DOI: 10.1007/s40124-014-0071-7

Source DB:  PubMed          Journal:  Curr Pediatr Rep


  58 in total

1.  Long-term T-cell reconstitution after hematopoietic stem-cell transplantation in primary T-cell-immunodeficient patients is associated with myeloid chimerism and possibly the primary disease phenotype.

Authors:  Marina Cavazzana-Calvo; Frédérique Carlier; Françoise Le Deist; Estelle Morillon; Pierre Taupin; David Gautier; Isabelle Radford-Weiss; Sophie Caillat-Zucman; Bénédicte Neven; Stephane Blanche; Rémi Cheynier; Alain Fischer; Salima Hacein-Bey-Abina
Journal:  Blood       Date:  2007-02-01       Impact factor: 22.113

2.  Malignancies after hematopoietic cell transplantation for primary immune deficiencies: a report from the Center for International Blood and Marrow Transplant Research.

Authors:  Naynesh R Kamani; Shimareet Kumar; Anna Hassebroek; Mary Eapen; Jennifer LeRademacher; James Casper; Morton Cowan; José Sánchez de Toledo; Alina Ferster; Paul Szabolcs; John R Wingard; Edwin Horwitz; Alexandra H Filipovich
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-20       Impact factor: 5.742

3.  Limited T cell receptor diversity of transplacentally acquired maternal T cells in severe combined immunodeficiency.

Authors:  C Knobloch; S F Goldmann; W Friedrich
Journal:  J Immunol       Date:  1991-06-15       Impact factor: 5.422

4.  Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches.

Authors:  Agnieszka Czechowicz; Daniel Kraft; Irving L Weissman; Deepta Bhattacharya
Journal:  Science       Date:  2007-11-23       Impact factor: 47.728

5.  Immune reconstitution in severe combined immunodeficiency disease after lectin-treated, T-cell-depleted haplocompatible bone marrow transplantation.

Authors:  Y Dror; R Gallagher; D W Wara; B W Colombe; A Merino; M Benkerrou; M J Cowan
Journal:  Blood       Date:  1993-04-15       Impact factor: 22.113

6.  Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis.

Authors:  Mary Dell Railey; Yuliya Lokhnygina; Rebecca H Buckley
Journal:  J Pediatr       Date:  2009-10-09       Impact factor: 4.406

7.  Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: results of the first 2 years.

Authors:  Antonia Kwan; Joseph A Church; Morton J Cowan; Rajni Agarwal; Neena Kapoor; Donald B Kohn; David B Lewis; Sean A McGhee; Theodore B Moore; E Richard Stiehm; Matthew Porteus; Constantino P Aznar; Robert Currier; Fred Lorey; Jennifer M Puck
Journal:  J Allergy Clin Immunol       Date:  2013-07       Impact factor: 10.793

8.  Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen.

Authors:  Kanchan Rao; Persis J Amrolia; Alison Jones; Catherine M Cale; Paru Naik; Doug King; Graham E Davies; H Bobby Gaspar; Paul A Veys
Journal:  Blood       Date:  2004-09-14       Impact factor: 22.113

9.  Cognitive and behavioral abnormalities in children after hematopoietic stem cell transplantation for severe congenital immunodeficiencies.

Authors:  Penny Titman; Elizabeth Pink; Emily Skucek; Katherine O'Hanlon; Tim J Cole; Jane Gaspar; Jinhua Xu-Bayford; Alison Jones; Adrian J Thrasher; E Graham Davies; Paul A Veys; H Bobby Gaspar
Journal:  Blood       Date:  2008-07-21       Impact factor: 22.113

10.  CD57 expression correlates with alveolitis severity in subjects with beryllium-induced disease.

Authors:  Brent E Palmer; Douglas G Mack; Allison K Martin; Lisa A Maier; Andrew P Fontenot
Journal:  J Allergy Clin Immunol       Date:  2007-04-09       Impact factor: 10.793

View more
  7 in total

1.  Immune reconstitution after HSCT in SCID-a cohort of conditioned and unconditioned patients.

Authors:  Uri Manor; Atar Lev; Amos J Simon; Daphna Hutt; Amos Toren; Bella Bielorai; Lior Goldberg; Tali Stauber; Raz Somech
Journal:  Immunol Res       Date:  2019-06       Impact factor: 2.829

2.  A general practitioner's guide to hematopoietic stem-cell transplantation.

Authors:  A Bazinet; G Popradi
Journal:  Curr Oncol       Date:  2019-06-01       Impact factor: 3.677

3.  Graft Versus Host Disease Following HLA-Matched Sibling Donor Compared with Matched Related Donor for Hematopoietic Stem Cell Transplantation for the Treatment of Severe Combined Immunodeficiency Disease.

Authors:  Bandar Al-Saud; Alhanouf Al-Saleem; Bashayer Al Rasheed; Abdulaziz Al-Ghonaium; Ali Al-Ahmari; Hamoud Al-Mousa; Amal Al-Seraihy; Rand Arnaout; Abdullah Al-Jefri; Sahar Elshorbagi; Nazeema Elsayed; Hasan Al-Dhekri; Mouhab Ayas; Saleh Al-Muhsen
Journal:  J Clin Immunol       Date:  2019-04-30       Impact factor: 8.317

4.  Transplacental maternal engraftment and posttransplantation graft-versus-host disease in children with severe combined immunodeficiency.

Authors:  Justin Wahlstrom; Kiran Patel; Erik Eckhert; Denice Kong; Biljana Horn; Morton J Cowan; Christopher C Dvorak
Journal:  J Allergy Clin Immunol       Date:  2016-06-16       Impact factor: 10.793

Review 5.  Immunological barriers to haematopoietic stem cell gene therapy.

Authors:  Carsten T Charlesworth; Ian Hsu; Adam C Wilkinson; Hiromitsu Nakauchi
Journal:  Nat Rev Immunol       Date:  2022-03-17       Impact factor: 108.555

Review 6.  Update on Clinical Ex Vivo Hematopoietic Stem Cell Gene Therapy for Inherited Monogenic Diseases.

Authors:  Francesca Tucci; Samantha Scaramuzza; Alessandro Aiuti; Alessandra Mortellaro
Journal:  Mol Ther       Date:  2020-11-20       Impact factor: 11.454

7.  Safety of tunneled central venous catheters in pediatric hematopoietic stem cell recipients with severe primary immunodeficiency diseases.

Authors:  Illya Martynov; Jessica Klima-Frysch; Wolfram Kluwe; Christoph Engel; Joachim Schoenberger
Journal:  PLoS One       Date:  2020-05-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.